Erbitux, for example, binds to a cell-surface protein called epidermal growth-factor receptor (EGFR).
例如，艾比特思和名为表皮生长因子受体(EGFR)的细胞表面蛋白的结合。
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
中国的非小细胞肺癌病人中吉非替尼敏感的表皮生长因子受体酪氨酸激酶区域的突变。
Objective To investigate the expression of inhibin, epidermal growth factor receptor in human ovarian granulosa cell tumor and their clinical significance.
目的研究抑制素、表皮生长因子受体在人卵巢颗粒细胞瘤中的表达及临床意义。
Objective to explore the relationship between epidermal growth factor receptor (EGFR) and cell proliferation and transformation.
目的探讨表皮生长因子受体与细胞增殖、转化的关系。
Clinicopathologic Significance of the Mutations of the Epidermal Growth Factor Receptor Gene in Patients with Non-Small Cell Lung Cancer.
非小细胞肺癌病人的表皮生长因子受体基因突变的临床病理意义。
Conclusion: Epidermal growth factor receptor inhibitor AG1487 may retard cell cycle, and then inhibit the proliferation of tumor cells.
结论：表皮生长因子受体抑制剂ag1487可对舌鳞癌细胞产生明显的增殖抑制作用。
This is the first FDA-approved, blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.
这是FDA批准的首个能够检测非小细胞肺癌患者表皮生长因子受体(EGFR)基因突变的、以血液为基础的基因检测试剂盒。
Purpose to study the expression and clinicopathological significance of epidermal growth factor receptor (EGFR) in oral squamous cell carcinoma (OSCC).
目的：研究表皮生长因子受体(EGFR)在口腔鳞癌组织中的表达及其临床病理学意义。
Objective To clone human epidermal growth factor receptor (HER2) gene and establish a MCF-7 cell line with stable co-expression of HER2 and estrogen receptor (ER).
目的克隆人表皮生长因子受体（HER2）基因，建立共表达HER2基因和雌激素受体（ER）基因的MCF-7细胞模型。
Objective to evaluate the clinical significance of epidermal growth factor receptor EGFR mutations in the treatment of non-small cell lung cancer NSCLC.
目的探讨外周血表皮生长因子受体(EGFR)基因突变在非小细胞肺癌(NSCLC)吉非替尼治疗适宜患者筛选中的价值。
Objective to evaluate the clinical significance of epidermal growth factor receptor EGFR mutations in the treatment of non-small cell lung cancer NSCLC.
目的探讨外周血表皮生长因子受体(EGFR)基因突变在非小细胞肺癌(NSCLC)吉非替尼治疗适宜患者筛选中的价值。
应用推荐